Skip to content

US · SHC · MEDICAL - DIAGNOSTICS & RESEARCH

Sotera Health Company (SHC) intrinsic value and stock valuation

$15.91as of 2026-11-21 · Mkt cap 5.38B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sotera Health Company DCF and intrinsic value

InvestorsCraft values SHC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SHC’s statements →

Sotera Health Company Graham Number

Graham Number: $3.63d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Broadview Heights, OH 44147 soterahealth.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$1.16B+7.3% 5y CAGRd
20182025
Net income
$78M
20182025
Free cash flow
$149.2M+17.3% 5y CAGRd
20182025
Total equity
$606M+5.9% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$1.16B$1.1B$1.05B$1B$931.5M
Operating income$392.8M$297.6M$276.7M$248.4M$256.7M
Net income$78M$44.4M$51.4M-$-233.57M$116.9M
EPSd$272.2K$155.8K$181.4K-$-833.88K$418.4K
Operating cash flow$287.2M$224.2M-$-147.73M$278M$281.6M
Capital expenditure-$-138.02M-$-179.07M-$-214.97M-$-182.38M-$-102.16M
Free cash flow$149.2M$45.1M-$-362.71M$95.6M$179.4M
Total assets$3.26B$3.07B$3.13B$3.12B$2.79B
Total debt$2.27B$2.35B$2.33B$2.03B$1.83B
Net debt$1.93B$2.07B$2.03B$1.64B$1.72B
Total equity$606M$404.9M$443.7M$350.2M$586.1M
Cash and short-term investments$346.5M$277.2M$296.4M$395.2M$106.9M
Income statement
20252024202320222021
Revenue$1.16B$1.1B$1.05B$1B$931.5M
Cost of revenue$518.1M$498.2M$472.1M$446.7M$412.8M
Gross profit$645.5M$602.3M$577.2M$557M$518.7M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$252.8M$242.6M$236.7M$245.7M$198.2M
Other expenses$0.00$62M$63.8M$62.9M$63.8M
Operating expenses$252.8M$304.7M$300.5M$308.7M$261.9M
Cost and expenses$770.9M$802.8M$772.6M$755.3M$674.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$155.7M$164.7M$142.9M$80.1M$74.2M
Depreciation and amortization$139M$163.6M$157.9M$145.6M$150.9M
Ebitda$442.3M$442.2M$406.8M-$-17.41M$400.8M
Operating income$392.8M$297.6M$276.7M$248.4M$256.7M
Total other income/expenses, net-$-245.27M-$-183.75M-$-170.66M-$-491.46M-$-81.02M
Income before tax$147.5M$113.9M$106M-$-243.11M$175.7M
Income tax expense$69.6M$69.5M$54.7M-$-9.54M$58.6M
Net income$78M$44.4M$51.4M-$-233.57M$116.9M
Weighted average shares outstanding$284M$282.8M$281M$280.1M$279.2M
Weighted average diluted shares outstanding$286.4M$284.9M$283.2M$280.1M$279.4M
Balance sheet
20252024202320222021
Cash and short-term investments$346.5M$277.2M$296.4M$395.2M$106.9M
Net receivables$176.3M$165.8M$175.5M$155.7M$134.1M
Inventory$59.4M$49.2M$48.3M$37.2M$54.3M
Total current assets$613.4M$526M$557.2M$645M$346M
Property, plant and equipment, net$1.16B$1.06B$971M$801M$690.7M
Goodwill and intangible assets$1.39B$1.4B$1.53B$1.59B$1.72B
Long-term investments$0.00$0.00$0.00$0.00$9.4M
Total non-current assets$2.65B$2.55B$2.57B$2.47B$2.44B
Total assets$3.26B$3.07B$3.13B$3.12B$2.79B
Accounts payable$78M$55.1M$71M$74.1M$72.9M
Short-term debt$23.2M$22.8M$19.5M$206.4M$10.5M
Deferred revenue$18M$15.1M$13.5M$12.1M$8.67M
Total current liabilities$249.6M$191M$230.7M$791.6M$161.2M
Long-term debt$2.25B$2.33B$2.31B$1.83B$1.82B
Deferred revenue, non-current$17.1M$16.8M$18.8M$18.9M$20.8M
Total non-current liabilities$2.41B$2.48B$2.46B$1.98B$2.04B
Capital lease obligations$123.7M$127.7M$98.6M$87.8M$84.3M
Total liabilities$2.66B$2.67B$2.69B$2.77B$2.2B
Common stock$2.86M$2.86M$2.86M$2.86M$2.86M
Retained earnings-$-532.09M-$-610.04M-$-654.44M-$-705.82M-$-472.25M
Accumulated other comprehensive income (loss)-$-109.84M-$-208.25M-$-92.68M-$-106.65M-$-83.57M
Total equity$606M$404.9M$443.7M$350.2M$586.1M
Total investments$0.00$0.00$0.00$0.00$9.4M
Total debt$2.27B$2.35B$2.33B$2.03B$1.83B
Net debt$1.93B$2.07B$2.03B$1.64B$1.72B
Cash flow statement
20252024202320222021
Net income$78M$44.4M$51.4M-$-233.57M$117.1M
Depreciation and amortization$139M$163.6M$160.3M$145.6M$150.9M
Stock-based compensation$30.9M$36.8M$32.2M$21.2M$13.9M
Change in working capital$28M-$-42.63M-$-403.29M$409.2M-$-12.59M
Accounts receivable$7.15M$2.22M-$-21.72M-$-12.55M-$-15.51M
Inventory-$-2.38M-$-4.75M-$-9.97M$14.4M-$-20.25M
Accounts payable$5.18M-$-6.64M-$-5.33M$1.11M$19.8M
Net cash provided by operating activities$287.2M$224.2M-$-147.73M$278M$281.6M
Investments in property, plant and equipment-$-138.02M-$-179.07M-$-214.97M-$-182.38M-$-102.16M
Acquisitions, net$0.00$0.00$0.00$450K-$-56.97M
Net cash used for investing activities-$-135.14M-$-179M-$-214.91M-$-181.9M-$-159.83M
Common stock issued-$-6.57M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-4.43M-$-4.09M-$-390K-$-1.43M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-100.53M-$-50.56M$266M$197.8M-$-117.29M
Net change in cash$67.6M-$-22.79M-$-94.64M$289.4M$4.47M
Cash at end of period$346.5M$278.9M$301.7M$396.3M$106.9M
Operating cash flow$287.2M$224.2M-$-147.73M$278M$281.6M
Capital expenditure-$-138.02M-$-179.07M-$-214.97M-$-182.38M-$-102.16M
Free cash flow$149.2M$45.1M-$-362.71M$95.6M$179.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sotera Health Company

        Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.

        CEO
        Alton E. Shader
        Employees
        3K
        Beta
        1.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Sotera Health Company (SHC)?

        Sotera Health Company (SHC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SHC undervalued?

        SHC trades at a price of $15.91 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.